CGF166

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

Conditions

Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

Trial Timeline

Jun 23, 2014 → Dec 9, 2019

NCT ID

NCT02132130

About CGF166

CGF166 is a phase 1/2 stage product being developed by Novartis for Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT02132130. Target conditions include Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss.

What happened to similar drugs?

0 of 1 similar drugs in Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss were approved

Approved (0) Terminated (0) Active (1)

🔄OMS302 + Phenylephrine HClOmeros CorporationPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02132130	Phase 1/2	Completed	Jun 23, 2014	Dec 9, 2019	Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

Competing Products

2 competing products in Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

See all competitors

Product	Company	Stage	Hype Score
OMS302 + Phenylephrine HCl	Omeros Corporation	Phase 3	34
SENS-111 100mg + SENS-111 200mg + Placebo Oral Tablet	Sensorion	Phase 2	25